I listened to a video presented by Sarah Busch, PhD, Pre-clinical Development, Athersys last week. Athersys is a small public biotech (ATHX) that is developing a stem cell therapy called MultiStem. It is in various phases of public trials to show safety and efficacy for acute inflammation resulting from a) stroke, b) acute respiratory distress syndrome (ARDS) and c) trauma, presently. Dr. Busch was detailing in her video (a summary of Athersys' pre-clinical programs) a use of MultiStem that would reduce inflammation that causes demylation, indicating that perhaps MultiStem could actually 'remylate' the damaged nerve endings. I am very excited about this possible indication, although it will be years before any trials are conducted, due to the smaller sizes of the total addessable markets for this indication. Nonetheless, I am trying to learn more about this possible future indication from Athersys. Disclosure: I am a shareholder in Athersys, but until last week, I had no idea that their product/therapy (if approved by the FDA) would also target PN or similar neurological ailments.